Handelsavisen
prelaunch
Companies Healthcare TARO.NS
TA
TARO.NS NSE (India) Medical Equipment, Supplies & Distribution

Taro.Ns

$214,70
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
12,3 %
ROE
4,7 %
Net margin
7,6 %
Debt / equity
0,54
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

TARO.NS operates in the healthcare services and equipment industry, primarily generating revenue through the distribution of medical equipment and supplies.

Business. TARO.NS operates in the healthcare services and equipment industry, primarily generating revenue through the distribution of medical equipment and supplies.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
4,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TARO.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TARO.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TARO.NS operates in the healthcare services and equipment industry, primarily generating revenue through the distribution of medical equipment and supplies.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    TARO.NS maintains a debt-to-equity ratio of 0.54, indicating a moderate level of leverage, and a current ratio of 1.38, suggesting adequate short-term liquidity to cover its obligations. However, the company's free cash flow is negative at -700,720,000 INR, which may signal pressure on liquidity and the need for external financing or operational improvements.

    The company's profitability is reflected in a return on equity (ROE) of 4.72% and a return on assets (ROA) of 2.76%. These figures are below the industry median for ROE and ROA, indicating that TARO.NS is underperforming its peers in terms of capital efficiency and asset utilization.

    TARO.NS does not disclose specific segment or geographic revenue breakdowns in the available data, making it difficult to assess the concentration of its revenue sources or geographic exposure. Analysts and investors should monitor any future disclosures for insights into the company's diversification strategy.

    The company's revenue for the latest period is 3,924,140,000 INR, and while no specific growth trajectory is provided, the negative free cash flow and capital expenditure of -1,517,070,000 INR suggest that the company is investing heavily in its operations, which could be a precursor to future growth.

    TARO.NS faces a medium liquidity risk, as indicated by its negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no near-term pressure expected. However, the negative free cash flow and high capital expenditure may necessitate future financing, which could lead to dilution.

    Recent events, including analyst estimates and financial performance, indicate a mixed outlook. The mean recommendation from analysts is 2.00, which is a "Hold" rating, with one "Buy" recommendation and no "Strong Buy" or "Sell" ratings. The last actual EPS was 5.60 INR, and the last actual revenue was 3,924,140,000 INR.

    Key takeaways
    • TARO.NS has a moderate level of leverage and adequate short-term liquidity.
    • The company's profitability metrics are below the industry median, indicating underperformance in capital efficiency and asset utilization.
    • The company is investing heavily in its operations, as evidenced by a significant capital expenditure.
    • TARO.NS faces a medium liquidity risk due to its negative net cash position.
    • Analysts have issued a "Hold" rating for the company, with one "Buy" recommendation and no "Strong Buy" or "Sell" ratings.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $214,70
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $6.30B
    Net cash
    -$3.39B
    Current ratio
    1.4
    Debt / equity
    0.5
    ROA
    2.8%
    ROE
    4.7%
    Cash conversion
    384.0%
    CapEx / revenue
    -38.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin12,3 %Above median
    Net Margin7,6 %Above median
    ROE4,7 %Above median
    Capex / Rev-38,7 %Bottom quartile
    D/E0,54Bottom quartile
    Cash Conv3,84Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • TARO.NS Market data — financials · 2026-05-29
    • Tarsons Products Ltd Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TARO.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage